Summary SDZ 280-446 is a semi-synthetic derivative of a natural cyclic peptolide. Its ability to sensitise in vitro tumour cells whose resistance is due to P-glycoprotein-mediated anticancer-drug efflux was shown using four different pairs of parental drug-sensitive (Par-) and multidrug-resistant (MDR-) cell lines, from three different species (mouse, human, Chinese hamster) representing four different cell lineages (monocytic leukaemia, nasopharyngeal epithelial carcinoma, colon epithelial carcinoma, ovary fibroblastoid carcinoma), and using four different drug classes (colchicine, vincristine, daunomycin/doxorubicin and etoposide). By measuring its capacity to restore normal drug sensitivity of MDR-cells in culture in vitro, it appeared that SDZ 280-446 belongs to the same class of very potent chemosensitisers as the cyclosporin derivative SDZ PSC 833: both are about one order of magnitude more active than cyclosporin A (CsA), which is itself about one order of magnitude more active than other known chemosensitisers (including verapamil, quinidine and amiodarone which have already entered clinical trials in MDR reversal). Low concentrations of SDZ 280-446 could also restore cellular daunomycin retention in MDR-P388 cells to the levels found in the Par-P388 cells. SDZ 280-446 was also effective as a chemosensitiser when given orally in vivo. In a syngeneic mouse model, combined therapy with vinca alkaloids given i.p. and SDZ 280-446 given per os for 5 consecutive days significantly prolonged the survival of MDR-P388 tumour-bearing mice, when compared with mice receiving vinca alkaloids alone. Another protocol, using three cycles of i.p. doxorubicin at 4 day intervals, could also not increase MDR-P388 tumour-bearing mouse survival unless the mice received SDZ 280-446 orally 4h before each doxorubicin injection. Though only very few combined therapy treatment protocols have been tested so far, clear increases in survival time of MDR-tumour-bearing mice were regularly obtained, leaving hope for major improvement of the therapy using other dosing schedules.
One of the major causes of therapeutic failure in cancer is the presence of intrinsically anticancer drug (ACD) resistant cells and/or to the emergence of resistant clones after repeated courses of chemotherapy. This problem is further exacerbated by the observation that these emerging tumours are often cross-resistant to other chemotherapeutic agents, even though these drugs were not used in the initial treatment, belong to unrelated structural classes and have different mechanisms of action. This phenomenon is widely known as 'multidrugresistance' (MDR) (Bellamy et al., 1990; Moscow & Cowan, 1990) .
A common mechanism by which tumour cells acquire MDR is the overexpression of a particular class of transmembrane glycoprotein, encoded by a small family of mdr genes and called the P-glycoprotein (Pgp). By rapidly pumping the ACD out of the MDR-tumour cells, Pgp molecules decrease the intracellular ACD concentration below its active (cytostatic) threshold. In vitro, it is possible to overcome this ACD-escape mechanism of MDR-cells by increasing the ACD concentration in the culture medium (Bradley et al., 1988; Endicott & Ling, 1989; Juranka et al., 1989) . However, this cannot be done in vivo since in clinical practice, cancer patient treatments are already performed with ACD regimens close to the maximal tolerated dose (MTD). As a consequence, MDR-tumours cannot be treated by some of the most effective ACD available today, since the doses required to reach cytostatic levels are unacceptably toxic if not lethal to the patient (Bellamy et al., 1990; Moscow & Cowan, 1990) .
Several studies have allowed the identification of a variety of agents which, in vitro, can decrease the ACD-resistance of MDR-tumour cells and sometimes completely restore their normal sensitivity to chemotherapeutic agents (Twentyman, 1988; Zamora et al., 1988; Ford et al., 1989; Georges et al., 1990; Hofsy & Nissen-Meyer, 1990) . Such chemosensitisers or 'Resistance-modulating' (RM) agents (RMA) belong to a variety of structural classes, though a high hydrophobicity and an ability to diffuse through the cell membrane seem to be common requirements. They seem to act by blocking the effluxing-function of Pgp, although this has not been conclusively shown in each case. Thus this functional neutralisation of the pump-causing MDR restores the normal accumulation and distribution of ACDs within the MDRtumour cells and therefore their sensitivity (Bradley et al., 1988; Endicott & Ling, 1989; Juranka et al., 1989; Georges et al., 1990) .
Early reports indicated the RM-activity of cyclosporin A (CsA; SandimmuneTM [Twentyman, 1988] ) seemed to be in vitro an order of magnitude higher than the RM-activity of several other RMAs such as verapamil, amiodarone and quinidine (Boesch et al., 1991a) , which have already entered clinical trials. Cyclosporin research has generated over a number of years a large family of related molecules in order to find compounds with improved immunosuppressive specificity and decreased host-toxicity. Their screening for RMactivity allowed us (Gaveriaux et al., 1989) to clearly separate the two known properties of the cyclosporin molecule, i.e. its immunosuppressive activity, possibly mediated through its interaction with cyclophilin (Takahashi et al., 1989) , and its MDR-reversing activity, possibly mediated through its interaction with Pgp (Foxwell et al., 1989) and led to the identification of SDZ PSC 833, a cyclosporin derivative endowed in vitro with the near maximally achievable MDR-reversing potency (Gaveriaux et al., 1991) . It is an order of magnitude more active than CsA to normalise the ACD-dependent growth inhibition of several MDR-tumour cell lines (Gaveriaux et al., 1991) . In vitro, at sub-micromolar concentrations, this RMA is capable of restoring to normal levels the intracellular ACD retention of MDR-tumour cells (Boesch et al., 1991b) . It is also active in vivo (Boesch et al., 1991c) , being able to restore chemotherapeutic responses of MDRtumour cells whose degree of resistance is much higher than that known to occur in cancer patients.
In parallel to our work on cyclosporins, a series of semisynthetic derivatives of the cyclic peptolide SDZ 90-215 which had been isolated initially as an antifungal agent from the fermentation broth of a strain of the Fungi imperfecti class (genus Septoria sp.) were studied for RM-activity, and a set of compounds was identified which showed high potency. From these, SDZ 280-446 was selected for further evaluation.
We now report on the properties of SDZ 280-446 whose outstanding RM- injections were prepared as described (Boesch et al., 1991c) .
Tumour cell lines
The cell lines belonged to three species and four cell classes covering all levels of adherence from none to very strong: the murine monocytic leukaemia P388N (Par-) and P388DoXR (MDR-), the Chinese hamster ovary (CHO) fibroblastoid carcinoma AUXB1 subclone ABlSII (Par-) and CHRC5 subclone C5S3.2 (MDR-), the human colon epithelial carcinoma LoVo (Par-) and LoVo/Dx (MDR-) and the human nasopharyngeal carcinoma KB-3-1 (Par-) and KB-V1 (MDR-). All MDR-cell lines were continuously grown in the presence of the drug used for their selection; 8 to 24 h before each experiment the culture medium of the MDR-cell lines was removed and the cells were grown in drug-free medium. The origins and detailed conditions for in vitro growth and analyses of these eight different cell lines were as published earlier (Gaveriaux et al., 1991) .
In vitro cytotoxicity studies Tumour cell growth and its drug-mediated inhibition were measured as described previously (Gaveriaux et al., 1989 (Gaveriaux et al., , 1991 Boesch et al., 1991a) . The growth levels obtained without RMA and ACD, but with their solvents were taken as representing 100% growth. The ACD IC50s (Table I) were calculated from the dose-response curves obtained by plotting the measured growth vs the ACD concentration as described previously (Gaveriaux et al., 1989) . Cultures performed in absence of ACD (but in the presence of its solvent) with the whole range of RMA concentrations allowed the construction of (RMA dose/cell growth response) curves and the determination of the RMA IC50s (Table I) (Boesch et al., 1991a; Gaveriaux et al., 1991 (Gaveriaux et al., 1991) .
Intracellular fluorescence studies for DA U retention They were performed in parallel with studies on the activity of SDZ PSC 833 and of a variety of other RMAs to restore DAU retention in MDR-P388 cells (see [Boesch et al., 1991b] for methodological procedures). [Boesch et al., 1991b] for details). In order to facilitate the comparison of the effects of the RMAs on the fluorescence levels of Par-P388 and MDR-P388 cells, the peak fluorescence levels (Y-axes) were plotted vs the RMA concentrations (X-axes) in the diagrams shown in this paper. In vivo studies They were performed in parallel to our in vivo studies of SDZ PSC 833 (Boesch et al., 1991c) , i.e. based on standard NCl protocols for screening new ACDs (Kallman, 1987) and adapted for studying RMA activity in mice bearing a moderately resistant MDR-P388 tumour (Tsuruo et al., 1981; Shinoda et al., 1989 In the different groups the MST were compared at T/C ratios (%) that is the ratio of survival time (in days) for treated mice (T) to untreated control mice (C). The significance of the survival data of drug-treated groups vs untreated groups or of combined vs single therapy were evaluated by 'P' values (student's t-test, unpaired data) (for further details, see Boesch et al., 1991c) . Though they did not allow distinction of the 'specific', i.e. nuclear, fluorescence from the whole cell fluorescence, flow cytometry analyses of DAU retention in Par-P388 and MDR-P388 cells provided less subjective comparison of the DAU retention in the two cell lines as a function of the RMA concentration. In the absence of RMA treatment, the MDR-P388 cells displayed low fluorescence levels corresponding to 4.5-5.8% of the Par-P388 cell fluorescence levels. Definite shifts of the fluorescence profiles of the RMAtreated MDR-P388 cell populations were observed at low concentrations of all three RMAs. As already described for several other RMAs (Boesch et al., 1991b) , these shifts were obtained at different concentrations and showed subtle differences for the different RMAs.
In order to facilitate the comparison of the effects of the RMAs on the fluorescence levels of Par-P388 and MDR-P388 cells, the peak fluorescence levels (Y-axes) were plotted vs the RMA concentrations (X-axes) in Figure 6 which compares SDZ PSC 833 and SDZ 280-446 with CsA. The lowest RMA concentrations sufficient to restore fully DAU retention in MDR-P388 cells were 30 fig ml' for CsA, 1-3 fg ml-' for SDZ PSC 833 and 3-10gml-' for SDZ 280-446. Therefore, by measuring the short term, RMA-mediated inhibition of Pgp function, SDZ PSC 833 was found to be about three times more active than SDZ 280-446 and 10-30 times more active than CsA.
In vivo efficacy of SDZ 280-446 Vinca alkaloids (VCR or VBL) as ACD Although they could prolong the survival of mice bearing the Par-P388 tumour cells, neither VCR nor VBL alone could significantly prolong the survival of MDR-P388 cell-grafted mice up to the high ACD dosages where they became severely toxic for the mice themselves (i.e. toxic for tumour-free mice) (Boesch et al., 1991c) .
Four independent experiments using vinca alkaloids allowed to evaluate the chemosensitising efficacy of SDZ 280-446 (Table III) . In all four experiments DBA/2 mice were grafted at Day 0 with five millions (parts A and B) or one million (parts C and D) Par-P388 or MDR-P388 tumour cells. Then, the RMA or its placebo was given by gavage per os and the vinca alkaloid was injected i.p. for 5 consecutive days.
The vinca alkaloids alone in the 15-100 igkg-' daily dosage range could not significantly prolong the survival of the mice bearing a MDR-tumour and were variably effective for mice grafted with Par-tumour cells. The daily treatment with 100 mg kg-' of SDZ 280-446 alone had also no significant effects on the survival of tumour-bearing mice. In contrast the vinca alkaloids could significantly increase, the survival of the MDR-tumour-bearing mice when administered i.p. together with SDZ 280-446 per os. The effect of SDZ 280-446 was dose-dependent, the 100 mg kg-' daily dosage appearing to be most effective for this treatment protocol. Curiously enough mice bearing Par-tumour and treated by the combined therapy could also show increased survival in comparison with mice treated with vinca alkaloid alone. Though this may be accounted for by an increased bioavailability of ACD when used in combination with it would not suffice to explain the higher efficacy of vinca alkaloids on the MDR-tumour: as mentioned earlier it was not possible to interfere with MDR-tumour growth-mediated mouse death by increasing the daily dosage of vinca alkaloids up to the doses which were severely toxic for tumour-free mice. Table IV . As expected, the treatment with DOX alone did not result in increased mouse survival (MST of 13.6 instead of 12.8 days). Similarly, no remarkable effects on mouse survival were observed in the groups treated with SDZ 280-446 alone. However, a highly significant prolongation of the survival of the MDR-P388 tumour-bearing mice was obtained by the combined therapy: with SDZ 280-446 (at 25 and 50 mg kg-' given 4 h before each DOX treatment), the mouse survival reached about 31 days, the combined therapy being thus roughly 2-3 fold more effective than the single DOX therapy.
Discussion
The ability of the cyclic peptolide SDZ 280-446 to sensitise in vitro tumour cells whose resistance is due to Pgp-mediated ACD efflux has been well documented for four different pairs of Par-and MDR-cell lines, from three different species (including two human cell line pairs) representing four different cell lineages, and using four different ACD classes. It is clear that SDZ 280-446 and the cyclosporin derivative SDZ PSC 833 (Gaveriaux et al., 1991; Boesch et al., 1991c) achieve the same high level of chemosensitisation which is about one order of magnitude more active than CsA, which is itself about one order of magnitude higher than other known chemosensitisers ( [Boesch et al., 1991a] (Boesch et al., 1991c) . In the latter case the effect of the combined therapy on the Par-tumour bearing recipients could be explained by an increased bioavailability of the ACD through alterations of the P450 system, as typical for cyclosporins. Such pharmacokinetic interactions also occur in the case of SDZ 280-446, but presently available data are still too fragmentary to allow a comparison with SDZ PSC 833. Whichever the increased ACD-bioavailability which is beneficial for Par-tumour bearing mice, it would not be sufficient for the MDR-tumour bearing mice since it was impossible to obtain any significant prolongation of survival of MDR-P388 tumour-bearing mice by increasing the daily dosage of vinca alkaloids (Boesch et al., 1991c Payne for discussions and for their help in the selection of SDZ 280-446, Peter Hiestand for confirming its lack of immunosuppressive activity, Peter Donatsch for communicating us his preliminary data on bioavailability and toxicology of SDZ 280-446.
